SCHEMBL2964279

SCHEMBL2964279

Nc1ccccc1S(=O)(=O)Nc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.56
KEAP1 Q14145 2/20 0.55
IL1RN P18510 1/20 0.55
ERAP1 Q9NZ08 1/20 0.55
GAA P10253 1/20 0.54
CA9 Q16790 2/20 0.53
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA12 O43570 1/20 0.52
CYP2C9 P11712 1/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52
CA14 Q9ULX7 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
MEN1 O00255 2/20 0.52
HTR6 P50406 2/20 0.52
ALDH1A1 P00352 1/20 0.52
PKM P14618 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL27500512 0.90 KMT2A (0.47) KMT2AKEAP1IL1RNERAP1GAA
SCHEMBL14940241 0.89 KEAP1 (0.62) KMT2AKEAP1GAACA9CA1
SCHEMBL27043141 0.87 KMT2A (0.51) KMT2AKEAP1IL1RNERAP1GAA
SCHEMBL7444314 0.85 CA1 (0.51) KMT2AKEAP1GAACA9CA1
Hydrochloric Acid SCHEMBL11745697 0.85 KMT2A (0.50) KMT2AKEAP1IL1RNERAP1GAA
SCHEMBL641594 0.85 CES1 (0.55) KMT2AKEAP1GAACA9CA1
SCHEMBL27176635 0.85 PKM (0.54) KMT2AKEAP1GAACA9CA1
SCHEMBL7627388 0.85 KEAP1 (0.67) KMT2AKEAP1IL1RNERAP1CA9
SCHEMBL15571014 0.85 MCL1 (0.53) KMT2ACA9MEN1HTR6ALDH1A1
SCHEMBL7508824 0.84 PGR (0.55) KMT2AKEAP1IL1RNERAP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4716529-A2 COMPOUNDS THAT RE-ACTIVATE MUTANT P53 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) 2026-04-01 EP disclosed
WO-2024243343-A2 COMPOUNDS THAT RE-ACTIVATE MUTANT P53 KARANICOLAS JOHN (US) 2024-11-28 WO disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
WO-2022094435-A1 MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE EMORY UNIVERSITY (US) 2022-05-05 WO disclosed
US-20210052603-A1 MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS EMORY UNIVERSITY 2021-02-25 US disclosed
US-8252841-B2 Methods of inhibiting bacterial virulence and compounds relating thereto THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-08-28 US disclosed
US-8252841-B2 Methods of inhibiting bacterial virulence and compounds relating thereto THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-08-28 US disclosed
US-7770534-B2 Changed condition indicator THERMOPROX 2010-08-10 US disclosed
US-20100048573-A1 Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2010-02-25 US disclosed
WO-2009088549-A2 METHODS OF INHIBITING BACTERIAL VIRULENCE AND COMPOUNDS RELATING THERETO THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-07-16 WO disclosed
EP-1994385-A2 CHANGED CONDITION INDICATOR Cooperman, Isadore (US) 2008-11-26 EP disclosed
US-20070238763-A1 Urea derivatives as integrin a4 antagonists LABORATORIOS ALMIRALL, S.A. 2007-10-11 US disclosed
US-20070238763-A1 Urea derivatives as integrin a4 antagonists LABORATORIOS ALMIRALL, S.A. 2007-10-11 US disclosed
EP-1383750-B1 UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS ALMIRALL LAB (ES) 2007-09-26 EP disclosed
WO-2007106463-A2 CHANGED CONDITION INDICATOR COOPERMAN ISADORE (US) 2007-09-20 WO disclosed
US-7253171-B2 Urea derivatives as integrin α4 antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-07 US disclosed
US-7253171-B2 Urea derivatives as integrin α4 antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-07 US disclosed
US-20070151502-A1 Changed condition indicator THERMOPROX 2007-07-05 US disclosed
US-5244860-A PRESSURE-SENSITIVE RECORDING AND TRANSFER MATERIAL CIBA-GEIGY CORPORATION (US) 1993-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052603-A1 MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS RORA, RORB, RORC KMT2A 1778/4885KEAP1 510/4885IL1RN 1335/4885
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 KMT2A 578/4885KEAP1 463/4885IL1RN 2011/4885
US-20070238763-A1 Urea derivatives as integrin a4 antagonists ITGB4, ITGA4, ITGB7 KMT2A 4075/4885KEAP1 4171/4885IL1RN 441/4885
US-20100048573-A1 Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto MMP8, SLC11A2, NFKBIA KMT2A 4400/4885KEAP1 776/4885IL1RN 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.